Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.72 |
| ▸ | HPGD | P15428 | 6/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | STS | P08842 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12475243 | 0.86 | ALDH1A1 (0.72) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL7116035 | 0.84 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL26195616 | 0.83 | MAOB (0.68) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL7504934 | 0.83 | ALDH1A1 (0.73) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL6665079 | 0.80 | ALDH1A1 (0.78) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| Hydrochloric Acid SCHEMBL8177838 | 0.79 | L3MBTL1 (0.62) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL7115071 | 0.79 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL10063475 | 0.78 | MAOB (0.74) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL29821752 | 0.78 | ALDH1A1 (0.62) | ALDH1A1KDM4EHPGDGAAHSD17B10 | |
| SCHEMBL17439465 | 0.77 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDGAAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2825261-A1 | POLYPEPTIDES AND THEIR USE | Novabiotics Limited (GB) | 2015-01-21 | — | — | EP | disclosed |
| US-20140155321-A1 | Polypeptides and Their Use | NOVABIOTICS LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| WO-2013136040-A1 | POLYPEPTIDES AND THEIR USE | NOVABIOTICS LIMITED (GB) | 2013-09-19 | — | — | WO | disclosed |
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2010-10-21 | — | — | US | disclosed |
| CN-101501015-A | Use of coumarin derivatives in antifungal therapy | NOVABIOTICS LTD (GB) | 2009-08-05 | — | — | CN | disclosed |
| EP-2049511-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | Novabiotics Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2007141513-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | NOVABIOTICS LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267653-A1 | USE OF COUMARIN DERIVATIVES IN ANTIFUNGAL THERAPY | DPM1, XPO5, NISCH | ALDH1A1 1883/4885KDM4E 3277/4885HPGD 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.